New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2

The 2004 discovery of EGFR mutations, followed by ALK rearrangements, ushered in a targeted therapy era for advanced non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting gene alterations have substantially improved survival and quality of life for patients with NSCLC. In the last...

Descripción completa

Detalles Bibliográficos
Autores principales: Olmedo, Maria Eugenia, Cervera, Raquel, Cabezon-Gutierrez, Luis, Lage, Yolanda, Corral de la Fuente, Elena, Gómez Rueda, Ana, Mielgo-Rubio, Xabier, Trujillo, Juan Carlos, Couñago, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052069/
https://www.ncbi.nlm.nih.gov/pubmed/35582653
http://dx.doi.org/10.5306/wjco.v13.i4.276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052069/
https://www.ncbi.nlm.nih.gov/pubmed/35582653
http://dx.doi.org/10.5306/wjco.v13.i4.276

Ejemplares similares